

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Antonio J. GRILLO-LOPEZ et al.

Application Serial No. 09/840,872

Filed: April 25, 2001

Title: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF
CENTRAL NERVOUS SYSTEM LYMPHOMAS

Group Art Unit: 1642

Examiner: Gary B. Nickol


* * * * *

AMENDMENT PURSUANT TO 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the official action dated December 12, 2003, wherein the claims were rejected under 35 U.S.C. § 102(b) and § 103(a) and under the judicially created doctrine of obviousness-type double patenting. The applicants traverse the outstanding rejections in view of the following amendments and remarks. This response is timely filed as it is accompanied by a petition for an extension of time to file in the second month with the requisite fee.



Addendum

Invention Title:

INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF
CENTRAL NERVOUS SYSTEM LYMPHOMAS